BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 27465588)

  • 1. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
    Maurer MJ; Bachy E; Ghesquières H; Ansell SM; Nowakowski GS; Thompson CA; Inwards DJ; Allmer C; Chassagne-Clément C; Nicolas-Virelizier E; Sebban C; Lebras L; Sarkozy C; Macon WR; Feldman AL; Syrbu SI; Traverse-Glehan A; Coiffier B; Slager SL; Weiner GJ; Witzig TE; Habermann TM; Salles G; Cerhan JR; Link BK
    Am J Hematol; 2016 Nov; 91(11):1096-1101. PubMed ID: 27465588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
    Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
    Maurer MJ; Ghesquières H; Jais JP; Witzig TE; Haioun C; Thompson CA; Delarue R; Micallef IN; Peyrade F; Macon WR; Jo Molina T; Ketterer N; Syrbu SI; Fitoussi O; Kurtin PJ; Allmer C; Nicolas-Virelizier E; Slager SL; Habermann TM; Link BK; Salles G; Tilly H; Cerhan JR
    J Clin Oncol; 2014 Apr; 32(10):1066-73. PubMed ID: 24550425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.
    Mondello P; Fama A; Larson MC; Feldman AL; Villasboas JC; Yang ZZ; Galkin I; Svelolkin V; Postovalova E; Bagaev A; Ovcharov P; Varlamova A; Huet S; Tesson B; McGrath KR; Slager S; Link BK; Syrbu S; Novak AJ; Habermann TM; Witzig TE; Nowakowski GS; Salles G; Cerhan JR; Ansell SM
    Blood Cancer J; 2021 Jul; 11(7):130. PubMed ID: 34267181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
    Wudhikarn K; Smith BJ; Button AM; Habermann TM; Thompson CA; Rosenstein LJ; Syrbu SI; Weiner GJ; Cerhan JR; Link BK
    Leuk Lymphoma; 2015; 56(8):2365-72. PubMed ID: 25530345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.
    Tracy SI; Maurer MJ; Witzig TE; Drake MT; Ansell SM; Nowakowski GS; Thompson CA; Inwards DJ; Johnston PB; Micallef IN; Allmer C; Macon WR; Weiner GJ; Slager SL; Habermann TM; Link BK; Cerhan JR
    Blood Cancer J; 2017 Aug; 7(8):e595. PubMed ID: 28841207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.
    Tracy SI; Larson MC; Feldman AL; Maurer MJ; Novak AJ; Slager SL; Villasboas JC; Allmer C; Habermann TM; Farooq U; Syrbu S; Cerhan JR; Link BK
    Am J Hematol; 2019 Jun; 94(6):658-666. PubMed ID: 30916801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
    J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    Maurer MJ; Ellin F; Srour L; Jerkeman M; Bennani NN; Connors JM; Slack GW; Smedby KE; Ansell SM; Link BK; Cerhan JR; Relander T; Savage KJ; Feldman AL
    J Clin Oncol; 2017 Dec; 35(36):4019-4026. PubMed ID: 29072976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
    Bachy E; Maurer MJ; Habermann TM; Gelas-Dore B; Maucort-Boulch D; Estell JA; Van den Neste E; Bouabdallah R; Gyan E; Feldman AL; Bargay J; Delmer A; Slager SL; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Ansell SM; Lamy T; Dartigues P; Link BK; Seymour JF; Cerhan JR; Salles G
    Blood; 2018 Jul; 132(1):49-58. PubMed ID: 29666118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma.
    Mihaljevic B; Jelicic J; Andjelic B; Antic D; Markovic O; Petkovic I; Jovanovic MP; Trajkovic G; Bila J; Djurasinovic V; Sretenovic A; Vukovic V; Smiljanic M; Balint MT
    Int J Hematol; 2016 Dec; 104(6):692-699. PubMed ID: 27714586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
    Maurer MJ; Jais JP; Ghesquières H; Witzig TE; Hong F; Haioun C; Thompson CA; Thieblemont C; Micallef IN; Porrata LF; Ribrag V; Nowakowski GS; Casasnovas O; Bologna S; Morschhauser F; Morrison VA; Peterson BA; Macon WR; Copie-Bergman C; Feldman AL; Syrbu SI; Kurtin PJ; Gascoyne RD; Li H; Allmer C; Kahl BS; Ansell SM; Slager SL; Link BK; Salles G; Habermann TM; Tilly H; Cerhan JR
    Am J Hematol; 2016 Feb; 91(2):179-84. PubMed ID: 26492520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
    Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
    J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.
    Nabhan C; Byrtek M; Rai A; Dawson K; Zhou X; Link BK; Friedberg JW; Zelenetz AD; Maurer MJ; Cerhan JR; Flowers CR
    Br J Haematol; 2015 Jul; 170(1):85-95. PubMed ID: 25851937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.